Company Encyclopedia
View More
name
Fushine
300497.SZ
Jiangxi Fushine Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, production, and sale of APIs and pharmaceutical intermediates in China and internationally. The company offers ß-lactamase inhibitors, carbapenem antibiotics, and antiviral drug intermediates; argatroban injection for the treatment of acute ischemic stroke; and doxycycline hydrochloride dispersible tablets to treat rickettsial diseases, mycoplasmal and chlamydial infections, relapsing fever, brucellosis, cholera, tularemia, plague, and chancroid. It also provides lithium-ion battery electrolyte additives; and microbial protein, amino acid water-soluble fertilizer, and other bio-fermentation products. The company was formerly known as Jingdezhen Fuxiang Pharmaceutical Co., Ltd and changed its name to Jiangxi Fushine Pharmaceutical Co., Ltd.
3.159 T
300497.SZMarket value -Rank by Market Cap -/-

Financial Score

06/12/2025 Update
D
PharmaceuticalsIndustry
Industry Ranking191/223
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreE
    • ROE-12.02%D
    • Profit Margin-28.11%E
    • Gross Margin2.89%E
  • Growth ScoreE
    • Revenue YoY-25.37%E
    • Net Profit YoY-50.51%D
    • Total Assets YoY-4.55%D
    • Net Assets YoY-9.19%D
  • Cash ScoreE
    • Cash Flow Margin-355.72%D
    • OCF YoY-25.37%E
  • Operating ScoreD
    • Turnover0.21D
  • Debt ScoreC
    • Gearing Ratio51.15%C

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Fushine Pharmaceutical Gains Approval For New Food Raw Material in China

    Fushine Pharmaceutical Gains Approval For New Food Raw Material in China

    marketscreener·
    SZ
    300497
    +1.59%
    marketscreener·
    SZ
    300497
    +1.59%

    Fushine Pharmaceutical Gets GMP Certification from Brazil for Tazobactam

    Fushine Pharmaceutical Gets GMP Certification from Brazil for Tazobactam

    marketscreener·
    SZ
    300497
    +1.59%
    marketscreener·
    SZ
    300497
    +1.59%

    A-share innovative drug concept stocks are active again, Sunshine Guojian Pharmaceutical rose over 10% to a new high, Yatai Pharm had two consecutive limit-ups, WECOME rose over 10%, and Baicheng Pharmaceutical, ALK, and Fushine followed suit

    Zhitong·
    SZ
    300878
    +0.33%
    SZ
    300497
    +1.59%
    SZ
    002940
    -1.44%
    Zhitong·
    SZ
    300878
    +0.33%
    SZ
    300497
    +1.59%
    SZ
    002940
    -1.44%

    Fushine: Net profit loss of 55.8404 million yuan in the third quarter, a decrease of 40.96%

    Fushine announced that its revenue for the third quarter was 255 million yuan, a decrease of 13.51%; the net profit loss was 55.8404 million yuan, a decrease of 40.96%. Revenue for the first three quarters was 769 million yuan, a decrease of 21.24%; the net profit loss was 62.7515 million yuan, a decrease of 1.09%

    Zhitong·
    SZ
    300497
    +1.59%
    Zhitong·
    SZ
    300497
    +1.59%

    A-share innovative drug concept stocks fluctuated and rose, Wolwo Pharma increased by over 10%, Chemexpress rose by over 9%, Fushine, CSBIO, and Medicilon followed suit

    Zhitong·
    SZ
    300357
    -1.49%
    SZ
    300255
    -0.96%
    SH
    688131
    +0.04%
    Zhitong·
    SZ
    300357
    -1.49%
    SZ
    300255
    -0.96%
    SH
    688131
    +0.04%
    © 2025 Longbridge｜Disclaimer